Bevacizumab for the treatment of recurrent glioblastoma
Following on from information provided to NICE by the company, the appraisal of Glioblastoma – bevacizumab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 80
Referral date 01 November 2008
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company, the appraisal of Glioblastoma – bevacizumab, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on our processes and methods, please see our CHTE processes and methods manual